Beneficial effects of lamivudine in hepatitis b virus-related decompensated cirrhosis

Journal of Hepatology

Volumn 33, Issue 2, 2000, Pages 308-312

  Kapoor, Dharmesh ^a   Guptan, Rajkumar C ^a   Wakil, Salma M ^a,b,c   Kazim, Syed N ^a,b   Kaul, Rachna ^a   Agarwal, Shri Ram ^a   Raisuddin, Sheikh ^b   Hasnain, Seyed E ^c   Sarin, Shiv K ^a,d  

^a G B PANT HOSPITAL   (India)

^b HAMDARD UNIVERSITY   (India)

^c NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

^d G ^*  (India)

Author keywords

Antivirals; Cirrhosis; Hepatitis B; Lamivudine; Nucleoside analogues

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; LAMIVUDINE; NUCLEOSIDE ANALOG; VIRUS DNA;

ADULT; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HOSPITALIZATION; HUMAN; LIVER CIRRHOSIS; LIVER FUNCTION; MALE; MORBIDITY; PRIORITY JOURNAL; SEROCONVERSION; VIRUS REPLICATION;

EID: 0033931789     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(00)80372-4     Document Type: Article

References (20)

1. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen positive chronic hepatitis B. Ann Intern Med. 119:1993;312-323.
2. Perrillo R, Tamburro C, Regenstein F, Balart L, Bodenheimer H, Silva M, et al. Low dose, titrable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology. 109:1995;908-916.
3. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA. 88:1991;8495-8499.
4. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med. 333:1995;1657-1661.
5. Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs AK, Rolles K, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet. 349:1997;364.
6. Bain VG, Kneteman NM, Ma MM, Gutfreund K, Shapiro JA, Fisher K, Tipples G, et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation. 62:1996;1456-1462.
7. Uan Leeuwen R, Katlama C, Kitchen V, Boucher CA, Tubiana R, McBride M, Ingrand D, et al. Evaluation of safety and efficacy of 3-TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I / II study. J Infect Dis. 171:1995;1166-1171.
8. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology. 30:1999;567-572.
9. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 339:1998;61-68.
10. Liaw YF. Acute exacerbation and superinfection in patients with chronic viral hepatitis. J Formos Med Assoc. 94:1995;521-528.
11. deJongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen positive cirrhosis of liver. Gastroenterology. 103:1992;1630-1635.
12. Lampertico P, Del Ninno F, Manzin A Danto MF, Rumi MG, Langhi G, et al. A randomized controlled trial of 24 month course interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in the serum. Hepatology. 26:1997;1621-1625.
13. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest. 102:1998;926-975.
14. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, et al. Efficacy of lamivudine in patients with hepatitis B e antigen negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology. 29:1999;889-896.
15. Guptan RC, Thakur V, Malhotra V, Sarin SK. Low dose recombinant interferon therapy in antiHBe positive chronic hepatitis B in Asian Indians. J Gastroenterol Hepatol. 13:1998;675-679.
16. Brunetto MR, Giarin M, Saracco G, Oiveri F, Calvo P, Capra G, et al. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology. 105:1993;845-850.
17. Tipples GA, Ma MM, Fisher KP, Bain VG, Kneteman NM, Tyrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology. 24:1996;714-717.
18. Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology. 27:1998;1711-1716.
19. Dienstag JL, Schiff ER, Mitchell M, Case DE Jr, Gitlin N, Lissoos T, et al. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology. 30:1999;1082-1087.
20. Villeneuve JP, Condreay LD, Williams B, Layrergues GP, Fenyves D, Bilodeau M, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology. 31:2000;207-210.